PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-31.28%
Negative net income growth while AGEN stands at 10.78%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
1.30%
Some D&A expansion while AGEN is negative at -0.30%. John Neff would see competitor’s short-term profit advantage unless expansions here deliver big returns.
No Data
No Data available this quarter, please select a different quarter.
41.15%
SBC growth well above AGEN's 60.88%. Michael Burry would flag major dilution risk vs. competitor’s approach.
170.16%
Well above AGEN's 48.03% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
170.16%
Lower 'other working capital' growth vs. AGEN's 1930.47%. David Dodd would see fewer unexpected short-term demands on cash.
169.42%
Some yoy increase while AGEN is negative at -382.65%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-4.39%
Negative yoy CFO while AGEN is 22.18%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
94.15%
CapEx growth well above AGEN's 33.47%. Michael Burry would suspect heavier cash outlays that risk short-term free cash flow vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Investing outflow well above AGEN's 33.47%. Michael Burry sees possible short-term FCF risk unless these invests pay off quickly vs. competitor’s approach.
No Data
No Data available this quarter, please select a different quarter.
-97.06%
Negative yoy issuance while AGEN is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.